All In Biotech

Drug Trial Radar · NCT00256750

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)

Last checked: Nov 20, 2026Latest source record: Aug 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 738 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

738

Actual

Start

Mar 2005

Primary completion

Jun 2008

Study completion Apr 2015

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.

Conditions

  • Kidney Transplantation
  • Chronic Kidney Failure

Interventions

  • Cyclosporine (CsA)Drug

    tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)

  • Belatacept LI (less intensive)Drug

    solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

  • Belatacept MI (more intensive)Drug

    solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants Surviving With a Functioning Graft by Month 12Time frame: Day 1 to Month 12
  2. Percent of Participants With a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12 or With a Decrease in mGFR Greater Than or Equal to 10 mL/Min/1.73m^2 From Month 3 to Month 12Time frame: Month 12; Month 3 to Month 12
  3. Percent of Participants Experiencing Acute Rejection (AR) Post-transplant by Month 12Time frame: Day 1 to Month 12

Locations

105 sites in 21 countries. Site status is shown where the registry gives one.

  • University Of Alabama At Birmingham

    Birmingham, Alabama

  • Loma Linda University Medical Center-Transplantation Institu

    Loma Linda, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • California Institute Of Renal Research

    San Diego, California

  • University Of California San Francisco Medical Center

    San Francisco, California

  • University Of Colorado Health Sciences Center

    Aurora, Colorado

  • Yale University School Of Medicine-Yale New Haven Hospital

    New Haven, Connecticut

  • Piedmont Hospital

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Medical College Of Georgia

    Augusta, Georgia

  • University Of Chicago Hospitals

    Chicago, Illinois

  • University Of Iowa Hospitals And Clinics

    Iowa City, Indiana

  • University Of Kentucky

    Lexington, Kentucky

  • Maine Tranplant Program

    Portland, Maine

  • Western New England Renal & Transplant Associates, Pc

    Springfield, Massachusetts

  • Henry Ford Hospital, Transplant Institute

    Detriot, Michigan

  • University Of Minnesota

    Minneapolis, Minnesota

  • Washington University School Of Medicine

    St Louis, Missouri

  • Recanati/Miller Transplantation Institute

    New York, New York

  • Columbia University College Of Physicians & Surgeons

    New York, New York

  • University Of Rochester Medical Center

    Rochester, New York

  • University Of North Carolina At Chapel Hill

    Chapel Hill, North Carolina

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Div Of Multi-Organ Trans, Hepato-Biliary-Pancreatic Surgery

    Philadelphia, Pennsylvania

  • Musc

    Charleston, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor University Medical Center

    Dallas, Texas

  • Fletcher Allen Health Care

    Burlington, Vermont

  • Inova Transplant Center

    Fairfax, Virginia

  • Swedish Medical Center

    Seattle, Washington

  • Sacred Heart Medical Ctr Providence Medical Research Ctr

    Spokane, Washington

  • University Of Wisconsin

    Madison, Wisconsin

  • Froedtert Memorial Lutheran Hospital

    Milwaukee, Wisconsin

  • Local Institution

    Buenos Aires, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    La Plata, Buenos Aires, Argentina

  • Local Institution

    Cordoba, Crd, Córdoba Province, Argentina

  • Local Institution

    Rosario, Santa Fe Province, Argentina

  • Local Institution

    Santa Fe, Santa Fe Province, Argentina

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.